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Hemodialysis vascular access dysfunction owing to stenosis
and thrombosis in polytetrafluoroethylene dialysis access
grafts is a huge clinical problem for which there are currently
no long lasting durable therapies. Vascular brachytherapy
has been used successfully for the prevention of coronary
restenosis following angioplasty and stent placement. The
Beta Radiation for Treatment of Arterial-Venous Graft
Outflow I study was a pilot study of vascular brachytherapy in
hemodialysis patients with patent but dysfunctional grafts.
Twenty-five patients were randomized to receive either
radiation therapy (a single dose of 18.4 Gy) or sham radiation,
following angioplasty. The primary efficacy end point of
the study was target lesion primary patency at 6 months.
The primary safety end point was a composite of death,
emergency surgery on the graft, venous rupture, or
aneurysm formation. Forty-two percent of the radiated grafts
achieved the target lesion primary patency end point at 6
months as compared to 0% of the control group (P¼ 0.015),
but this did not translate into an improvement in secondary
patency at either 6 or 12 months. Radiation therapy was
found to be safe in the setting of hemodialysis vascular
access dysfunction. Our results suggest that vascular
brachytherapy is an intervention that is worthy of further
examination in the setting of non-thrombosed dialysis access
grafts.
Kidney International (2006) 70, 2006–2013. doi:10.1038/sj.ki.5001869;
published online 11 October 2006
KEYWORDS: vascular brachytherapy; dialysis access stenosis; thrombosis;
safety
Hemodialysis vascular access dysfunction is currently an
important cause of morbidity and hospitalization in the
hemodialysis population (approximately 300 000 patients in
the United States).1 The vast majority of hemodialysis
vascular dysfunction is due to venous stenosis followed by
thrombosis in polytetrafluoroethylene (PTFE) dialysis access
grafts which comprise approximately 40% of all permanent
dialysis access in the United States, although some regions
have a higher prevalence.2,3 At a cellular level, venous stenosis
in the setting of PTFE dialysis grafts is due to venous
neointimal hyperplasia, which is characterized by smooth
muscle cell/myofibroblast proliferation and migration,
microvessel formation, or angiogenesis within the venous
neointima and the presence of a macrophage layer lining
both surfaces of PTFE graft.4–8 At a clinical level, PTFE
dialysis grafts have a dismal primary patency (as low as 23%
at 1 year and 4% at 2 years in some studies) and require an
average of 1.22 procedures/year (greater than 200 000
annually) in order to maintain patency (0.54 angioplasties,
0.51 thrombectomies, and 0.17 surgical revisions per patient
year).9 Unfortunately the results following angioplasty of
dialysis access grafts are very poor with only a 40%, 3-month
primary patency for thrombosed PTFE dialysis grafts and a
50%, 6-month patency for patent but dysfunctional
grafts.10,11 Consequently hemodialysis vascular access dys-
function has been estimated to have an economic cost of over
one billion dollars per annum or $8000 per annum for each
at risk patient.12–14 This is in addition to a huge negative
impact on the quality of life of hemodialysis patients, who
already have multiple co-morbidities. Despite the magnitude
of the clinical problem, however, there are currently no long
lasting and durable therapies for the prevention or treatment
of hemodialysis vascular access dysfunction.2
Radiation therapy has been shown at an in vitro level to
inhibit the proliferation of all three cell types involved in the
lesion of venous stenosis in PTFE dialysis grafts (smooth
muscle cells, macrophages, and endothelial cells in micro-
vessels).15–17 At an experimental level vascular brachytherapy
(endovascular radiation therapy) can inhibit post-angioplasty
coronary restenosis.18,19 In addition experimental studies in
pig models of arteriovenous graft stenosis have demonstrated
a reduction in neointimal hyperplasia and luminal stenosis
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with external beam,20 and endovascular21 radiation therapy.
Finally at a clinical level, numerous reports have documented
a significant decrease in coronary restenosis following
vascular brachytherapy.22–24 The most relevant clinical
information (from coronary studies) with regard to venous
stenosis in PTFE dialysis grafts, however, comes from the
SVG WRIST study25 which was able to demonstrate a
beneficial effect of vascular brachytherapy in the setting of
saphenous vein graft stenosis. Additional data on the
feasibility and safety of using vascular brachytherapy
clinically for venous stenosis comes from a subset analysis
of the RENO trial.26 In terms of current cardiology clinical
practice, however, vascular brachytherapy is not as effective
as drug eluting stents for the prevention of restenosis
following angioplasty and stent placement.27,28 More recently,
studies have demonstrated that placement of a drug eluting
stent is superior to vascular brachytherapy, even in the setting
of restenosis of a bare metal stent.29,30 Drug eluting stents,
however, are currently not available for clinical use in patients
with hemodialysis vascular access dysfunction.
Despite the significant experimental and clinical data
supporting the use of radiation therapy for vascular stenosis,
there is a surprising paucity of data on the use of radiation
therapy in the setting of dialysis access stenosis. Before the
current study, the only data available for vascular brachy-
therapy following angioplasty of dialysis access grafts was a
small nonrandomized study from the Emory Clinic which
demonstrated the safety of this procedure.31 In addition
Cohen et al.32 have published on a small randomized study of
external beam radiation therapy, following dialysis access
stenosis. This study demonstrated a trend towards a better
outcome in the radiation group although this was not
statistically significant. Unfortunately, the study group was
very heterogenous and included PTFE grafts, primary
arteriovenous fistulae, and brachiobasilic transpositions.
We report herein on the BRAVO I (Beta Radiation for
Treatment of Arterial-Venous Graft Outflow) trial, which was
a randomized pilot study of vascular brachytherapy therapy
for patent (non-thrombosed) but dysfunctional PTFE dialysis
access grafts.
RESULTS
Sixty-five patients agreed to participate in the BRAVO 1 trial
from nine different institutions. Forty patients did not
qualify for the trial (screen failures), primarily because they
failed to meet the angiographic inclusion and exclusion
criteria such as the requirement for an absence of tandem
stenoses, or the need for a 50% stenosis at the graft-vein
anastomosis (see Table 3). Thus 25 patients from six different
institutions (see Appendix A) were randomized to either
Radiation (n¼ 14) or sham radiation (Controls; n¼ 11). 2
patients died before a 6-month angiogram. Both patients
were in the Radiation group. The causes of death were
myocardial infarction and sepsis. Both deaths were thought
to be unrelated to the study treatment. These patients have
not been included in the outcome results as they did not have
the 6-month angiogram needed for the primary efficacy
endpoint. Both patients appeared to have functioning grafts
at the time of death. In addition, two other patients in the
study died after completion of the 6-month angiogram, one
each in the Radiation and Control groups. The cause of death
in both these patients was thought to be sepsis.
Demographics and vascular access history
Table 1 shows the demographics of the Radiation and
Control groups. In keeping with the current demographics of
hemodialysis patients in the United States, the mean age for
both groups was 64 years with diabetes mellitus being the
leading cause of end-stage renal disease. African Americans
constituted 36% of the total study population. Table 2
describes the location (forearm versus upper arm) and
configuration (straight versus loop) of the current hemo-
dialysis graft and also the number of previous accesses. Both
groups appeared similar albeit with more loop grafts in the
Radiation group. In addition, there were no differences
between the two groups with respect to dialysis adequacy (Kt/V
and urea reduction ratio).
Table 1 | Demographics
Radiation (n=14) Control (n=11)
Age 64.5 64.7
Gender 8 M, 6 F 5 M, 6 F
Ethnicity
Caucasian 9 6
Black 5 4
Other 0 1
Years on hemodialysis (years)
1 3 2
1–3 7 6
3–5 2 3
45 2 0
ESRD cause
Diabetes 7 7
Hypertension 3 3
Glomerulonephritis 1 0
Others 3 1
ESRD, end-stage renal disease; F, female; M, male.
Table 2 | Hemodialysis access history
Radiation (n=14) Placebo (n=11)
No. of prior accesses
1 Prior access 13 10
2 Prior accesses 1 1
Location of current access
Forearm 8 6
Upper arm 6 5
Configuration of current access
Loop 11 4
Straight 3 7
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Screen failures
Table 3 summarizes the reasons for angiographic screen
failures (see also Figure 5 for protocol algorithm). The main
reasons were tandem stenoses (25%) or a false-positive
Transonics blood flow (20%).
Treatment indices
Finally, there were no differences between the radiation and
control groups with regard to the severity or length of
stenosis of the target lesion, the response to angioplasty
(residual stenosis), and the reference vessel diameter
(Table 4).
Efficacy outcomes
Patients in the Radiation group had a significant improve-
ment (P¼ 0.015; w2 analysis, Figure 1) in post-intervention
target lesion primary patency at 6 months (41.6%) as
compared to the Control Group (0%). One patient each in
the Radiation and Control groups had a thrombosis of the
graft that was followed by placement of a new access. There is
no angiographic data in these two patients and they have
been included as post-intervention target lesion primary
patency failures. If these two patients are removed from the
analysis, the Radiation group would have a post-intervention
target lesion primary patency rate of 45% (5/11) as compared
to 0% (0/10) in the Control group. One patient who was in
the radiation group was found to have an arterial stenosis at
the time of the 6-month angiogram with no stenosis of the
target lesion. Thus primary patency of the entire dialysis
access circuit in the Radiation group was 33% (4/12) as
compared to 0% in the Control group (P¼ 0.035). However,
this improvement in both post-intervention target lesion
primary patency and post-intervention primary patency did
not translate into an improvement in post-intervention
secondary patency at 6 months (Figure 2) which was 92% in
the Radiation group as compared to 91% in the Control
group (P¼NS). However, in order to achieve similar
secondary patency rates at 6 months, more interventions
were performed in the Control group as compared to the
Radiation group (13 vs 9). Interestingly both the straight
grafts (2/2) in the Radiation group did not achieve post-
intervention target lesion primary patency at 6 months
whereas 50% of the loop grafts (5/10) in the Radiation group
did achieve this end point. In the Control group, 7/7 straight
grafts did not achieve this end point as also 4/4 loop grafts.
Although loop grafts appeared to do better than straight
grafts in the Radiation group we believe that the numbers are
far too small for any definitive analysis. Of note one patient
each with a loop and straight graft died during the study.
These patients have not been included.
Safety outcomes
In view of existing concerns over a possible linkage between
radiation therapy and thrombosis, regardless of stenosis, we
also assessed the thrombosis free rate (defined as a lack of
graft thrombosis) in the two groups over the 6-month study
period. The Radiation group had a thrombosis free rate at
Table 3 | Angiographic screen failures
Cause Number (%)
Tandem stenoses 10 (25)
False-positive transonics flow 8 (20)
Central venous stenosis only 4 (10)
Arterial inflow stenosis only 2 (5)
Reference vein diameter48 mm 2 (5)
Intragraft stenosis only 3 (7.5)
Lesion length too long (46 cm) 4 (10)
Treatment failure 1 (2.5)
Not reported 6 (15)
Table 4 | Angiography and angioplasty comparisons
Radiation (n=14) Control (n=11) P-value
Reference vein diameter 6.971.1 6.871.0 0.89
Pre-angioplasty stenosis 73.077.8 74.8714.9 0.54
Lesion length (cm) 2.771.3 1.971.2 0.15
Percent residual stenosis 15.179.9 8.578.8 0.25
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Figure 1 | Target lesion primary patency rate. Note the significant
improvement with vascular brachytherapy.
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Figure 2 | Secondary patency rate at 6 months. The improvement
in target lesion primary patency did not translate into a difference in
secondary patency.
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6 months (Figure 3) of 10/12 (83%) as compared to 8/11
(73%) in the control group (P¼NS). Two of the three
thromboses in the Control group occurred following the
index angioplasty. Both occurred 63 days post-angioplasty.
The third thrombosis in the Control group occurred 2 days
following an angioplasty for a restenosis of the target lesion,
96 days after the index angioplasty. One thrombosis in the
Radiation group occurred 2 days following the index
angioplasty and radiation. This graft was abandoned. The
second thrombosis in the Radiation group occurred 36 days
following angioplasty for a restenotic lesion (this angioplasty
was performed 31 days following the index angioplasty).
Special attention was paid to complications occurring
during the interventional procedure. Four complications
occurred during 88 procedures performed during the
screening, treatment, and follow-up portions of the study.
Three of these were in the screen failure group; a hematoma,
a balloon rupture, and a pseudoaneurysm. In addition there
was a small venous dissection during the screening
angioplasty procedure. This patient was not included in the
study.
In all 191 adverse event reports were filed during the
course of this study. This included all episodes of stenosis
and/or thrombosis (discussed above), which were classified as
having a possible relationship to radiation. These have been
discussed above. The only other adverse effect that was
classified as having a possible relationship to radiation was a
skin ulcer over the graft, which resulted in exposure of the
graft. This occurred in a patient in the Control group. The
vast majority of the adverse effects reported were related to
the underlying very significant co-morbidities present in
hemodialysis patients. There were no significant concerns
raised about the side effect profile in either the control or
radiation patients by the Data Safety Monitoring Board.
Transonics blood flow
Figure 4 summarizes the mean intragraft blood flow in the
Radiation and Control groups at the time of initial screening,
at the first hemodialysis session post-randomization and at
monthly intervals thereafter for 6 months (or until
thrombosis or stenosis). Although there were no differences
between the two groups in intragraft blood flows before or
immediately after angioplasty, patients in the Radiation
group had significantly better blood flows at the 3- month
(P¼ 0.03), 4- month (P¼ 0.03), and 6-month time points
(P¼ 0.005). In addition there was an overall decline in blood
flow over time in the Control group but not in the Radiation
group. Specifically, there was a statistically significant
difference between mean blood flow at month 1 and that
at months 2 (P¼ 0.014), 3 (P¼ 0.008), 4 (P¼ 0.039), and
5 (P¼ 0.018) in the Control group. The only statistically
significant result that was identified when a similar analysis
was performed for the Radiation group was a difference
between the month 4 and month 6 blood flows (P¼ 0.044).
The clinical significance of this is unclear.
12-Month follow-up results
Although the primary end points of the BRAVO I study were
at 6 months, data collection has continued after the study,
and secondary patency data is available on nine patients in
the Radiation group and seven patients in the Control group
at 1 year post-enrollment. 44% of patients (4/9) in the
Radiation group were still dialyzing through the index graft
at this time as compared to 57% of patients (4/7) in the
Control group.
DISCUSSION
The BRAVO I clinical trial is the first randomized study of
vascular brachytherapy for the treatment of dialysis access
stenosis. Although our results suggest a beneficial effect of
this intervention on the primary efficacy end point of post-
intervention target lesion primary patency and also on the
secondary end point of post-intervention primary patency
(for the entire dialysis access circuit), it is important to note
that these positive effects did not translate into an
improvement in secondary patency at 6 months. However,
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Figure 3 | Thrombosis rate during study period. There was no
difference in the thrombosis rates between the two groups.
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Figure 4 | Transonics blood flows. Intragraft blood flows in the
Radiation group were significantly better than in the Placebo group
from 3 months onwards. In addition, there was a decrement in
Transonics blood flows from month 1 onwards in the Control group,
which did not occur in the Radiation group.
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the reduction in the number of interventions needed could
potentially translate into some economic benefits at the
6-month time point. In addition, available 12-month data
also does not demonstrate an increase in secondary patency
(44% for Radiation vs 57% for the Controls), suggesting that
radiation therapy may have only a short-lived effect or even
a negative long-term effect (although our numbers at 12
months are extremely small).
A particular concern with endovascular radiation therapy
has always been an increased risk of thrombotic episodes.
There were no differences in thrombotic episodes between
the radiation and control groups in this study. It should be
noted, however, that both episodes of vascular thrombosis in
the radiation group occurred following the index procedure,
whereas all the thrombotic episodes in the control group
occurred following a second angioplasty.
As noted in the Results section, the control group had a
0% target lesion primary patency and also 0% primary
patency at 6 months. This is clearly worse than expected
although previous individual studies have also reported very
poor results.9 It should be emphasized, however, that this was
a randomized study and the poor results in our control group
are likely to be an indicator of the complexity and poor
prognosis of dialysis vascular access in hemodialysis patients,
with their many concurrent morbidities.
In addition to potential efficacy, a key finding of the
BRAVO I study was the demonstration of the safety of this
procedure in the complex setting of uremic hemodialysis
patients with PTFE dialysis grafts and significant clinical co-
morbidity (two deaths during the course of the study and
two further deaths during the period of continuing follow-
up). Our results suggest that the safety profile of vascular
brachytherapy in this population is acceptable and we believe
that this is critically important information not only with
regard to future larger studies, but also with regard to the off
label use of this therapy in particularly recalcitrant patients
who have exhausted other vascular access options.
Interestingly, the post-angioplasty Transonics blood flows
were significantly better in the Radiation group as compared
to the Control group from the 2-month time point onwards,
owing to a stabilization of blood flow. It is unclear as to
whether beneficial positive remodeling owing to radiation
as reported by a number of groups was responsible for
this.33–35
In conclusion, we believe that the BRAVO I study is an
important addition to the clinical information available on
anti-stenotic therapies for hemodialysis vascular access
dysfunction. It must be emphasized that the BRAVO I study
is a pilot study, which has demonstrated to us the possible
benefits of vascular brachytherapy in the setting of dialysis
access grafts. The small numbers of patients in this study,
however, do not permit us to make any definitive conclusions
that could have an impact on current clinical practice. How-
ever, at a minimum, we believe that the BRAVO I study has:
(a) demonstrated the safety of endovascular radiation therapy
in patients with dialysis access stenosis and (b) provided the
background data for a larger study of radiation therapy in
patients with dysfunctional dialysis access grafts.
MATERIALS AND METHODS
The BRAVO I was a randomized double blind multi-center pilot
study to assess the effect of vascular brachytherapy on the 6-month
post-intervention target lesion primary patency rate in hemodialysis
patients with patent (non-thrombosed) but dysfunctional (de-
creased Transonics blood flow) grafts. Each enrolling site received
Institutional Review Board and Radiation Safety Approval before
consenting and enrolling patients in the trial.
Basic protocol
The basic protocol for the BRAVO I study is described in Figure 5.
Full informed consent was obtained from all patients. Hemodialysis
patients with patent but dysfunctional PTFE dialysis grafts, who
were greater than 18 years of age, were identified on the basis of
decreased intra graft blood flows using the TransonicsTM device.
Patients with (a) an intragraft access blood of less than 800 ml/min
or (b) an intragraft access blood flow of less than 1000 ml/min,
which had decreased by greater than 25% over the previous 4
months were assessed for non-angiographic exclusion criteria. These
included a known hypercoagulability state, allergy, or sensitivity to
anti-platelet or anti-coagulant therapy, the presence of less than two
other potential access sites and the presence of a thrombosed graft or
a clinical need for thrombectomy and thrombolysis. If they satisfied
these criteria they were sent for an angiogram. Angiographic
inclusion criteria included the presence of a single stenosis greater
than 50% at the graft-vein anastomosis (target lesion), a post-
angioplasty residual stenosis of less than 30%, a venous outflow
injury intervention length (VOIIL) of less than 6 cm beyond the
leading edge of the anastomosis and a reference vessel diameter of
4–8 cm. Angiographic exclusion criteria included tandem stenoses
anywhere in the dialysis circuit from the artery supplying the graft to
the right atrium or the presence of a stent at the planned treatment
site. The magnitude of stenosis was determined by published
reporting standards of the Society of Interventional Radiology.36
Patients with suitable lesions initially underwent a conventional
angioplasty. All lesion/vessel injury lengths were recorded by
angiography in order to determine the extent of vessel injury
(VOIIL), which influenced the extent (length) of subsequent
radiation therapy. Patients with a residual stenosis of less than
30% who had a reference vessel diameter of less than or equal to
8 mm (no balloon size available for a larger vein; see below) and a
VOIIL of less than 6 cm (in order to provide complete radiation
HD patient Transonics flow
meets criteria
Meets all clinical and 
demographic criteria
Consent Meets all angiographic inclusion criteria Angioplasty success
Enroll patient Randomize
Sr-90
Placebo
or
Follow-up 
end points
Figure 5 | Basic protocol. This algorithm for the BRAVO I study
emphasizes the presence of non-angiographic (clinical) and
angiographic inclusion/exclusion criteria.
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coverage of the area of vascular injury; see below) were randomized
to receive either sham radiation therapy or vascular brachytherapy
using the Novoste ‘Corona’ system (see below).
Vascular brachytherapy treatment
The four lumen (Figure 6, left top inset) Corona delivery system
(Figure 6) that has been successfully used in the coronary setting was
used for the BRAVO I study. This comprises a centering balloon
catheter which uses carbon dioxide (in order to standardize
radiation delivery to the vessel wall) and incorporates a four-lumen
design including a 0.35 inch guide wire lumen, fluid send and return
lumens, and a lumen for inflating the centering balloon with carbon
dioxide. Balloon sizes from 5–8 mm were used for this study
(Figure 6, top right inset). Following conventional angioplasty the
carbon dioxide filled balloon was inflated to 1–2 atm and a
strontium 90 radioactive source train containing 24 miniature
radioactive seeds (Figure 7) was delivered to cover the entire length
of balloon injury (Figures 7 and 8). Fluorescent tape markers were
utilized to ensure that the entire region of vascular injury was
radiated (Figure 8). The system was calibrated such that patients
received a dose of 18.4 Gy, 0.5 mm into the vein wall. All patients
were anticoagulated with heparin before the vascular brachytherapy
procedure with the target activated coagulation time being greater
than 250 s. Building upon the experience acquired from previous
studies of endovascular radiation therapy and current FDA
recommendations,37 the BRAVO protocol incorporated strict guide-
lines to ensure that the entire area of injury was irradiated with
adequate margins in order to avoid the ‘candy wrapper’ effect
(aggressive rebound stenosis at the edges of the radiated zone)
described in earlier studies of vascular brachytherapy in the
coronary circulation. Specifically, patients with a VOIIL of greater
than 6 cm beyond the leading edge of the graft-vein anastomosis
were excluded as the maximal length of vascular injury that could be
radiated in this study was 6 cm (two 5 cm length applications of the
strontium 90 source with a requirement for a 1 cm overlap into
graft, a 1 cm overlap between the two source train applications and a
1 cm overlap beyond the site of vascular injury). In addition patients
with a reference vein diameter of 48 mm were excluded because of
Delivery system
Balloon 
inflator
4 lumen corona 
catheter
Figure 6 | Corona delivery system. The Corona delivery system
consists of a plunger device (with a separate balloon inflator), which
is attached to a four lumen catheter (top left inset). This ends in a
special Corona balloon (see Figure 7), which is available in different
sizes (top right inset).
Catheter
marker
Catheter
marker
ILC
Prescribed
dose
length
(5.5 cm)
Figure 7 | Expanded representation of the corona radiation
delivery balloon. Note the 60 mm long radioactive source train
which is made up of twenty four 2.5 mm long strontium 90 seeds.
The radioactive source train is inserted through one of the lumens
once the delivery catheter balloon is in the right place (determined
by the proximal and distal markers, see Figure 8).
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Figure 8 | Vascular brachytherapy procedure. (a) The typical lesion
that was targeted in this study; a tight stenosis at the graft-vein
anastomosis (horizontal arrow). (b) Following placement of the
radio-opaque ruler wire a wire was passed across the stenosis. The
stenotic lesion then underwent a successful angioplasty with a 7 mm
ID  2 cm long balloon. A liberal estimate of the extent of vascular
injury (VOIIL) at this time would be from the 70 mm marker to
the 110 mm marker (including 1 cm extra on either side). (c) The
post-angioplasty film with the radio opaque markers. The Corona
delivery catheter was then positioned so that it covered the entire
region of vascular injury. (d) Note that the proximal and distal
radiation markers are at 120 mm and 70 mm (black arrows). (e) The
Corona balloon was then inflated (white arrowheads in post-bead
removal) and the radioactive source train was introduced (inset
(e); from different patient). Finally (f) A post-angioplasty,
post-vascular brachytherapy film (arrow shows angioplasty site).
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the lack of a suitable Corona balloon. All patients were started onto
either Aspirin (81 or 325 mg) or Plavix (75 mg) for the duration of
the study in order to avoid potential problems with late
thrombosis.37
Patients randomized to receive sham radiation therapy under-
went an identical process, albeit with the delivery of a non-
radioactive source train to the injury site. The identity of patient
treatment was only known to the radiation physicist.
Post-procedure follow-up
Patients received clinical follow-up at their first hemodialysis session
and monthly thereafter. All patients were required to return for a
6-month angiogram, unless they had already reached the study
endpoint (see below). All patients also underwent monthly
Transonics flow measurements and were referred for an angiogram
if graft blood flow fell below 800 ml/min or if patients had a greater
than 25% drop in flow with a final flow of o1000 ml/min. A
detailed vascular history (all percutaneous or surgical interventions
and episodes of thrombosis) following the index procedure was
collected on all patients. All adverse events and hospital admissions
were recorded.
Outcomes and end points
The primary efficacy endpoint of the study was post-intervention
target lesion primary patency at 6 months by angiography. This was
defined according to the SIR guidelines as the occurrence of access
thrombosis or the need for intervention within the treatment area.
The primary safety endpoint was a composite endpoint of death,
emergency surgery on the graft, venous rupture, or aneurysm
formation or enlargement at 6 months. Secondary endpoints
included post-intervention primary patency (defined as a stenosis
anywhere within the access circuit), post-intervention secondary
patency defined as the surgical revison or abandonment of the access
(i.e., grafts could undergo repeated angioplasties to keep the access
patent and would not reach the secondary end point) and graft
thrombosis at 6 months. Please note that primary and secondary
patency do not refer to target lesion versus lesions at other places
within the access circuit. In addition, Transonics blood flows were
measured before angioplasty, at the first hemodialysis session post-
angioplasty and at monthly intervals thereafter until the 6-month
angiogram or prior intervention/thrombosis of the graft (primary
patency end point). Thus the target lesion primary patency and
the primary patency data were obtained in the context of
angiograms being performed for decreased blood flow, and also
for all patients who had not reached the primary end point at 6
months. All complications were recorded by the clinical sites. All
serious adverse events were adjudicated by an independent Data
Safety Monitoring Board.
Angiographic analyses
All angiograms were evaluated by a core laboratory (Montreal Heart
Institute), with the radio-opaque ruler in place. (Figure 8) A
dedicated brachytherapy software analysis package (Medical Ima-
ging Systems) developed by Medis Corporation (Leiden, The
Netherlands) was used. Angiograms of the successful interventional
procedure were obtained in subtracted and non-subtracted images
on either plain film support or recorded on compact disc in DICOM
format. All images were analyzed with the radiopaque ruler in
place. The purpose of this ruler was: (1) to calculate a calibration
factor that allows the computer assisted package to obtain
absolute measurements in millimeter, and (2) to verify the precise
positioning of proximal and distal margins of each VOILL and each
subsequent vascular brachytherapy treatment. These physical land-
marks are part of the dedicated brachytherapy software analysis
package developed by Medis Corporation and are essential to
calculate relevant parameter measurements in subsegments such as
injured, irradiated, and fall off zone segments. Image acquisition
included non-subtracted images for recording the positioning of all
balloon dilations and all brachytherapy sources. The angiographic
acquisition phases with contrast material (i.e. pre-dilation, post-
dilation, and final post-radiation) included at least one partially
subtracted image to allow visualization of bony landmarks and of
the radiopaque ruler. These angiographic images were converted
into a proper file format so they could be read and analyzed with the
brachytherapy analysis software. The images of interest were then
displayed on a video monitor, and, by the use of an automatic edge
detection program, vessel contours were determined by assessing
brightness along scan lines perpendicular to the centerline of the
vessel. The resulting edge strength values were input to minimal cost
analysis contour-detection algorithm, which searches for an optimal
contour path along the entire segment. The calibration factor
calculated from the projected radiopaque ruler (pixel size ranging
from 0.22 to 0.32 mm) allowed absolute measurements of the
minimal lumen diameter, reference vein diameter; interpolated
method), length of stenosis, length of balloon injuries (VOILL), and
length as well as positioning of radiation sources.
Statistical analysis
Differences in post-intervention primary patency, post-intervention
secondary patency, and post-intervention thrombosis rate were
analyzed using a w2 analysis (StatView 5, SAS Institutes, Cary, NC,
USA). Differences in Transonics blood flows between the Radiation
and Control groups were analyzed using an analysis of variance test,
whereas differences between Transonics blood flows at different time
points within the same group (Radiation or Control) were assessed
with a paired t-test. A P-value of less than 0.05 was considered to be
significant.
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APPENDIX A
The BRAVO I sites that enrolled subjects included:
University of Cincinnati (Cincinnati, OH, USA) 01
Piedmont Hospital of Atlanta (Atlanta, GA, USA) 02
OSF St Francis Medical Center (Peoria, IL, USA) 03
Mayo Clinic/St Mary’s Hospital (Rochester, MI, USA) 05
Louisiana State University Hospital at Shreveport
(Shreveport, LA, USA) 07
Baptist Medical Center (Jacksonville, FL, USA) 12
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